{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:39:12Z","timestamp":1792795152860,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gene editing methods are an attractive therapeutic option for Duchenne muscular dystrophy, and they have an immediate application in the generation of research models. To generate myoblast cultures that could be useful in in vitro drug screening, we have optimised a CRISPR\/Cas9 gene edition protocol. We have successfully used it in wild type immortalised myoblasts to delete exon 52 of the dystrophin gene, modelling a common Duchenne muscular dystrophy mutation; and in patient\u2019s immortalised cultures we have deleted an inhibitory microRNA target region of the utrophin UTR, leading to utrophin upregulation. We have characterised these cultures by demonstrating, respectively, inhibition of dystrophin expression and overexpression of utrophin, and evaluating the expression of myogenic factors (Myf5 and MyH3) and components of the dystrophin associated glycoprotein complex (\u03b1-sarcoglycan and \u03b2-dystroglycan). To demonstrate their use in the assessment of DMD treatments, we have performed exon skipping on the DMD\u039452-Model and have used the unedited DMD cultures\/ DMD-UTRN-Model combo to assess utrophin overexpression after drug treatment. While the practical use of DMD\u039452-Model is limited to the validation to our gene editing protocol, DMD-UTRN-Model presents a possible therapeutic gene edition target as well as a useful positive control in the screening of utrophin overexpression drugs.<\/jats:p>","DOI":"10.1038\/s41598-021-97730-5","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T06:03:16Z","timestamp":1631599396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Duchenne muscular dystrophy cell culture models created by CRISPR\/Cas9 gene editing and their application in drug screening\u00a0"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7804-8763","authenticated-orcid":false,"given":"Patricia","family":"Soblechero-Mart\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edurne","family":"Albiasu-Arteta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Anton-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0835-7069","authenticated-orcid":false,"given":"Laura","family":"de la Puente-Ovejero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iker","family":"Garcia-Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Gonz\u00e1lez-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Larra\u00f1aga-Aiestaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4711-7495","authenticated-orcid":false,"given":"Andrea","family":"L\u00f3pez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Poyatos-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Est\u00edbaliz","family":"Ruiz-Del-Yerro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7703-3255","authenticated-orcid":false,"given":"Virginia","family":"Arechavala-Gomeza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"key":"97730_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman, E. P., Brown, R. H. Jr. & Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919\u2013928. https:\/\/doi.org\/10.1016\/0092-8674(87)90579-4 (1987).","journal-title":"Cell"},{"key":"97730_CR2","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1093\/brain\/awr291","volume":"134","author":"K Anthony","year":"2011","unstructured":"Anthony, K. et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: Implications for clinical trials. Brain 134, 3547\u20133559. https:\/\/doi.org\/10.1093\/brain\/awr291 (2011).","journal-title":"Brain"},{"key":"97730_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/s1474-4422(03)00585-4","volume":"2","author":"F Muntoni","year":"2003","unstructured":"Muntoni, F., Torelli, S. & Ferlini, A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2, 731\u2013740. https:\/\/doi.org\/10.1016\/s1474-4422(03)00585-4 (2003).","journal-title":"Lancet Neurol."},{"key":"97730_CR4","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1172\/JCI36612","volume":"119","author":"Y Lai","year":"2009","unstructured":"Lai, Y. et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Invest. 119, 624\u2013635. https:\/\/doi.org\/10.1172\/JCI36612 (2009).","journal-title":"J. Clin. Invest."},{"key":"97730_CR5","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1177\/0883073810371129","volume":"25","author":"RS Finkel","year":"2010","unstructured":"Finkel, R. S. Read-through strategies for suppression of nonsense mutations in Duchenne\/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J. Child. Neurol. 25, 1158\u20131164. https:\/\/doi.org\/10.1177\/0883073810371129 (2010).","journal-title":"J. Child. Neurol."},{"key":"97730_CR6","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","volume":"8","author":"M Kinali","year":"2009","unstructured":"Kinali, M. et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 8, 918\u2013928. https:\/\/doi.org\/10.1016\/S1474-4422(09)70211-X (2009).","journal-title":"Lancet Neurol."},{"key":"97730_CR7","doi-asserted-by":"crossref","unstructured":"Muntoni, F. et al. Golodirsen induces exon skipping leading to sarcolemmal dystrophin expression in duchenne muscular dystrophy patients with mutations amenable to exon 53 skipping (S22.001). Neurology 90 (2018).","DOI":"10.1016\/S0960-8966(18)30304-3"},{"key":"97730_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/mus.20586","volume":"34","author":"A Aartsma-Rus","year":"2006","unstructured":"Aartsma-Rus, A., Van Deutekom, J. C., Fokkema, I. F., Van Ommen, G. J. & Den Dunnen, J. T. Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34, 135\u2013144. https:\/\/doi.org\/10.1002\/mus.20586 (2006).","journal-title":"Muscle Nerve"},{"key":"97730_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2174\/156652312800840621","volume":"12","author":"V Arechavala-Gomeza","year":"2012","unstructured":"Arechavala-Gomeza, V., Anthony, K., Morgan, J. & Muntoni, F. Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: Progress and challenges. Curr. Gene Ther. 12, 152\u2013160. https:\/\/doi.org\/10.2174\/156652312800840621 (2012).","journal-title":"Curr. Gene Ther."},{"key":"97730_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1484","author":"JR Mendell","year":"2020","unstructured":"Mendell, J. R. et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy: A nonrandomized controlled trial. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1484 (2020).","journal-title":"JAMA Neurol."},{"key":"97730_CR11","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1089\/hum.2018.012","volume":"29","author":"D Duan","year":"2018","unstructured":"Duan, D. Micro-dystrophin gene therapy goes systemic in duchenne muscular dystrophy patients. Hum. Gene Ther. 29, 733\u2013736. https:\/\/doi.org\/10.1089\/hum.2018.012 (2018).","journal-title":"Hum. Gene Ther."},{"key":"97730_CR12","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.15252\/emmm.201505636","volume":"7","author":"G Cossu","year":"2015","unstructured":"Cossu, G. et al. Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. EMBO Mol. Med. 7, 1513\u20131528. https:\/\/doi.org\/10.15252\/emmm.201505636 (2015).","journal-title":"EMBO Mol. Med."},{"key":"97730_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2019.113086","volume":"323","author":"C Sun","year":"2020","unstructured":"Sun, C., Serra, C., Lee, G. & Wagner, K. R. Stem cell-based therapies for Duchenne muscular dystrophy. Exp. Neurol. 323, 113086. https:\/\/doi.org\/10.1016\/j.expneurol.2019.113086 (2020).","journal-title":"Exp. Neurol."},{"key":"97730_CR14","doi-asserted-by":"publisher","first-page":"19750","DOI":"10.1038\/srep19750","volume":"6","author":"J Meng","year":"2016","unstructured":"Meng, J. et al. Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy. Sci. Rep. 6, 19750. https:\/\/doi.org\/10.1038\/srep19750 (2016).","journal-title":"Sci. Rep."},{"key":"97730_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/360591a0","volume":"360","author":"JM Tinsley","year":"1992","unstructured":"Tinsley, J. M. et al. Primary structure of dystrophin-related protein. Nature 360, 591\u2013593. https:\/\/doi.org\/10.1038\/360591a0 (1992).","journal-title":"Nature"},{"key":"97730_CR16","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/4033","volume":"4","author":"J Tinsley","year":"1998","unstructured":"Tinsley, J. et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat. Med. 4, 1441\u20131444 (1998).","journal-title":"Nat. Med."},{"key":"97730_CR17","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/sj.gt.3301941","volume":"10","author":"M Cerletti","year":"2003","unstructured":"Cerletti, M. et al. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer. Gene Ther. 10, 750\u2013757. https:\/\/doi.org\/10.1038\/sj.gt.3301941 (2003).","journal-title":"Gene Ther."},{"key":"97730_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/384349a0","volume":"384","author":"JM Tinsley","year":"1996","unstructured":"Tinsley, J. M. et al. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 384, 349\u2013353. https:\/\/doi.org\/10.1038\/384349a0 (1996).","journal-title":"Nature"},{"key":"97730_CR19","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0960-8966(01)00220-6","volume":"11","author":"R Fisher","year":"2001","unstructured":"Fisher, R. et al. Non-toxic ubiquitous over-expression of utrophin in the mdx mouse. Neuromuscul. Disord. 11, 713\u2013721 (2001).","journal-title":"Neuromuscul. Disord."},{"key":"97730_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrg3460","volume":"14","author":"RJ Fairclough","year":"2013","unstructured":"Fairclough, R. J., Wood, M. J. & Davies, K. E. Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat. Rev. Genet. 14, 373\u2013378. https:\/\/doi.org\/10.1038\/nrg3460 (2013).","journal-title":"Nat. Rev. Genet."},{"key":"97730_CR21","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/jcph.468","volume":"55","author":"J Tinsley","year":"2015","unstructured":"Tinsley, J., Robinson, N. & Davies, K. E. Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers. J. Clin. Pharmacol. 55, 698\u2013707. https:\/\/doi.org\/10.1002\/jcph.468 (2015).","journal-title":"J. Clin. Pharmacol."},{"key":"97730_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152840","volume":"11","author":"V Ricotti","year":"2016","unstructured":"Ricotti, V. et al. Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to pediatric patients with duchenne muscular dystrophy. PLoS ONE 11, e0152840. https:\/\/doi.org\/10.1371\/journal.pone.0152840 (2016).","journal-title":"PLoS ONE"},{"key":"97730_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182676","volume":"12","author":"MK Mishra","year":"2017","unstructured":"Mishra, M. K., Loro, E., Sengupta, K., Wilton, S. D. & Khurana, T. S. Functional improvement of dystrophic muscle by repression of utrophin: let-7c interaction. PLoS ONE 12, e0182676. https:\/\/doi.org\/10.1371\/journal.pone.0182676 (2017).","journal-title":"PLoS ONE"},{"key":"97730_CR24","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.omtn.2020.08.031","volume":"22","author":"K Sengupta","year":"2020","unstructured":"Sengupta, K. et al. Genome editing-mediated utrophin upregulation in Duchenne muscular dystrophy stem cells. mol Ther Nucleic Acids 22, 500\u2013509. https:\/\/doi.org\/10.1016\/j.omtn.2020.08.031 (2020).","journal-title":"mol Ther Nucleic Acids"},{"key":"97730_CR25","doi-asserted-by":"publisher","first-page":"21492","DOI":"10.1038\/s41598-020-76338-1","volume":"10","author":"K Sengupta","year":"2020","unstructured":"Sengupta, K., Loro, E. & Khurana, T. S. PMO-based let-7c site blocking oligonucleotide (SBO) mediated utrophin upregulation in mdx mice, a therapeutic approach for Duchenne muscular dystrophy (DMD). Sci. Rep. 10, 21492. https:\/\/doi.org\/10.1038\/s41598-020-76338-1 (2020).","journal-title":"Sci. Rep."},{"key":"97730_CR26","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/s41591-019-0594-0","volume":"25","author":"Y Song","year":"2019","unstructured":"Song, Y. et al. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. Nat Med 25, 1505\u20131511. https:\/\/doi.org\/10.1038\/s41591-019-0594-0 (2019).","journal-title":"Nat Med"},{"key":"97730_CR27","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1089\/hum.2015.088","volume":"28","author":"M Ito","year":"2017","unstructured":"Ito, M., Ehara, Y., Li, J., Inada, K. & Ohno, K. Protein-anchoring therapy of Biglycan for Mdx mouse model of Duchenne muscular dystrophy. Hum Gene Ther 28, 428\u2013436. https:\/\/doi.org\/10.1089\/hum.2015.088 (2017).","journal-title":"Hum Gene Ther"},{"key":"97730_CR28","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.bbadis.2018.01.030","volume":"1172\u20131182","author":"C Pisani","year":"1864","unstructured":"Pisani, C. et al. Utrophin up-regulation by artificial transcription factors induces muscle rescue and impacts the neuromuscular junction in mdx mice. Biochim Biophys Acta Mol Basis Dis 1172\u20131182, 2018. https:\/\/doi.org\/10.1016\/j.bbadis.2018.01.030 (1864).","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"97730_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12735","author":"P Soblechero-Martin","year":"2021","unstructured":"Soblechero-Martin, P., Lopez-Martinez, A., de la Puente-Ovejero, L., Vallejo-Illarramendi, A. & Arechavala-Gomeza, V. Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies. Neuropathol Appl Neurobiol https:\/\/doi.org\/10.1111\/nan.12735 (2021).","journal-title":"Neuropathol Appl Neurobiol"},{"key":"97730_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/2044-5040-1-34","volume":"1","author":"K Mamchaoui","year":"2011","unstructured":"Mamchaoui, K. et al. Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skelet Muscle 1, 34. https:\/\/doi.org\/10.1186\/2044-5040-1-34 (2011).","journal-title":"Skelet Muscle"},{"key":"97730_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cell.2015.12.035","volume":"164","author":"AV Wright","year":"2016","unstructured":"Wright, A. V., Nunez, J. K. & Doudna, J. A. Biology and applications of CRISPR systems: Harnessing nature\u2019s toolbox for genome engineering. Cell 164, 29\u201344. https:\/\/doi.org\/10.1016\/j.cell.2015.12.035 (2016).","journal-title":"Cell"},{"key":"97730_CR32","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/bit.25490","volume":"112","author":"Z He","year":"2015","unstructured":"He, Z. et al. Highly efficient targeted chromosome deletions using CRISPR\/Cas9. Biotechnol. Bioeng. 112, 1060\u20131064. https:\/\/doi.org\/10.1002\/bit.25490 (2015).","journal-title":"Biotechnol. Bioeng."},{"key":"97730_CR33","doi-asserted-by":"publisher","first-page":"6244","DOI":"10.1038\/ncomms7244","volume":"6","author":"DG Ousterout","year":"2015","unstructured":"Ousterout, D. G. et al. Multiplex CRISPR\/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 6, 6244. https:\/\/doi.org\/10.1038\/ncomms7244 (2015).","journal-title":"Nat Commun"},{"key":"97730_CR34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.stem.2016.01.021","volume":"18","author":"CS Young","year":"2016","unstructured":"Young, C. S. et al. A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell 18, 533\u2013540. https:\/\/doi.org\/10.1016\/j.stem.2016.01.021 (2016).","journal-title":"Cell Stem Cell"},{"key":"97730_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.aau1549","volume":"362","author":"L Amoasii","year":"2018","unstructured":"Amoasii, L. et al. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science 362, 86\u201391. https:\/\/doi.org\/10.1126\/science.aau1549 (2018).","journal-title":"Science"},{"key":"97730_CR36","doi-asserted-by":"publisher","first-page":"eaav4324","DOI":"10.1126\/sciadv.aav4324","volume":"5","author":"YL Min","year":"2019","unstructured":"Min, Y. L. et al. CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells. Sci. Adv. 5, eaav4324. https:\/\/doi.org\/10.1126\/sciadv.aav4324 (2019).","journal-title":"Sci. Adv."},{"key":"97730_CR37","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1016\/j.ymthe.2018.08.010","volume":"26","author":"BL Duchene","year":"2018","unstructured":"Duchene, B. L. et al. CRISPR-induced deletion with SaCas9 restores dystrophin expression in dystrophic models in vitro and in vivo. Mol Ther 26, 2604\u20132616. https:\/\/doi.org\/10.1016\/j.ymthe.2018.08.010 (2018).","journal-title":"Mol Ther"},{"key":"97730_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228072","volume":"15","author":"S Mata Lopez","year":"2020","unstructured":"Mata Lopez, S. et al. Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy. PLoS ONE 15, e0228072. https:\/\/doi.org\/10.1371\/journal.pone.0228072 (2020).","journal-title":"PLoS ONE"},{"key":"97730_CR39","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth, C. T. et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med 25, 249\u2013254. https:\/\/doi.org\/10.1038\/s41591-018-0326-x (2019).","journal-title":"Nat Med"},{"key":"97730_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/genes11030342","author":"KRQ Lim","year":"2020","unstructured":"Lim, K. R. Q., Nguyen, Q., Dzierlega, K., Huang, Y. & Yokota, T. CRISPR-generated animal models of duchenne muscular dystrophy. Genes https:\/\/doi.org\/10.3390\/genes11030342 (2020).","journal-title":"Genes"},{"key":"97730_CR41","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13059-016-1012-2","volume":"17","author":"M Haeussler","year":"2016","unstructured":"Haeussler, M. et al. Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. 17, 148\u2013148. https:\/\/doi.org\/10.1186\/s13059-016-1012-2 (2016).","journal-title":"Genome Biol."},{"key":"97730_CR42","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1056\/NEJMoa073108","volume":"357","author":"JC van Deutekom","year":"2007","unstructured":"van Deutekom, J. C. et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357, 2677\u20132686. https:\/\/doi.org\/10.1056\/NEJMoa073108 (2007).","journal-title":"N Engl J Med"},{"key":"97730_CR43","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson, C. E. et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351, 403\u2013407. https:\/\/doi.org\/10.1126\/science.aad5143 (2016).","journal-title":"Science"},{"key":"97730_CR44","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.aad5177","volume":"351","author":"M Tabebordbar","year":"2016","unstructured":"Tabebordbar, M. et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407\u2013411. https:\/\/doi.org\/10.1126\/science.aad5177 (2016).","journal-title":"Science"},{"key":"97730_CR45","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1126\/science.aad5725","volume":"351","author":"C Long","year":"2016","unstructured":"Long, C. et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351, 400\u2013403. https:\/\/doi.org\/10.1126\/science.aad5725 (2016).","journal-title":"Science"},{"key":"97730_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2015.11.012","author":"D Wojtal","year":"2015","unstructured":"Wojtal, D. et al. Spell checking nature: Versatility of CRISPR\/Cas9 for developing treatments for inherited disorders. Am. J. Hum. Genet. https:\/\/doi.org\/10.1016\/j.ajhg.2015.11.012 (2015).","journal-title":"Am. J. Hum. Genet."},{"key":"97730_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.nmd.2009.10.013","volume":"20","author":"LJ Popplewell","year":"2010","unstructured":"Popplewell, L. J. et al. Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials. Neuromuscul. Disord. 20, 102\u2013110. https:\/\/doi.org\/10.1016\/j.nmd.2009.10.013 (2010).","journal-title":"Neuromuscul. Disord."},{"key":"97730_CR48","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1089\/hum.2006.061","volume":"18","author":"V Arechavala-Gomeza","year":"2007","unstructured":"Arechavala-Gomeza, V. et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum. Gene Ther. 18, 798\u2013810. https:\/\/doi.org\/10.1089\/hum.2006.061 (2007).","journal-title":"Hum. Gene Ther."},{"key":"97730_CR49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.coph.2017.04.002","volume":"34","author":"S Guiraud","year":"2017","unstructured":"Guiraud, S. & Davies, K. E. Pharmacological advances for treatment in Duchenne muscular dystrophy. Curr. Opin. Pharmacol. 34, 36\u201348. https:\/\/doi.org\/10.1016\/j.coph.2017.04.002 (2017).","journal-title":"Curr. Opin. Pharmacol."},{"key":"97730_CR50","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41598-020-58737-6","volume":"10","author":"E Loro","year":"2020","unstructured":"Loro, E. et al. High-throughput identification of post-transcriptional utrophin up-regulators for Duchenne muscle dystrophy (DMD) therapy. Sci. Rep. 10, 2132. https:\/\/doi.org\/10.1038\/s41598-020-58737-6 (2020).","journal-title":"Sci. Rep."},{"key":"97730_CR51","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2990.2009.01056.x","volume":"36","author":"V Arechavala-Gomeza","year":"2010","unstructured":"Arechavala-Gomeza, V. et al. Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression. Neuropathol. Appl. Neurobiol. 36, 265\u2013274. https:\/\/doi.org\/10.1111\/j.1365-2990.2009.01056.x (2010).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"97730_CR52","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/nan.12448","volume":"44","author":"E Ruiz-Del-Yerro","year":"2018","unstructured":"Ruiz-Del-Yerro, E., Garcia-Jimenez, I., Mamchaoui, K. & Arechavala-Gomeza, V. Myoblots: dystrophin quantification by in-cell western assay for a streamlined development of Duchenne muscular dystrophy (DMD) treatments. Neuropathol. Appl. Neurobiol. 44, 463\u2013473. https:\/\/doi.org\/10.1111\/nan.12448 (2018).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"97730_CR53","doi-asserted-by":"publisher","first-page":"6241681","DOI":"10.1155\/2018\/6241681","volume":"2018","author":"N Jiwlawat","year":"2018","unstructured":"Jiwlawat, N., Lynch, E., Jeffrey, J., Van Dyke, J. M. & Suzuki, M. Current progress and challenges for skeletal muscle differentiation from human pluripotent stem cells using transgene-free approaches. Stem Cells Int. 2018, 6241681. https:\/\/doi.org\/10.1155\/2018\/6241681 (2018).","journal-title":"Stem Cells Int."},{"key":"97730_CR54","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/(sici)1097-4644(20000101)76:1<118::aid-jcb12>3.3.co;2-6","volume":"76","author":"MA Melone","year":"1999","unstructured":"Melone, M. A., Peluso, G., Petillo, O., Galderisi, U. & Cotrufo, R. Defective growth in vitro of Duchenne Muscular Dystrophy myoblasts: The molecular and biochemical basis. J. Cell Biochem. 76, 118\u2013132. https:\/\/doi.org\/10.1002\/(sici)1097-4644(20000101)76:1%3c118::aid-jcb12%3e3.3.co;2-6 (1999).","journal-title":"J. Cell Biochem."},{"key":"97730_CR55","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281\u20132308. https:\/\/doi.org\/10.1038\/nprot.2013.143 (2013).","journal-title":"Nat. Protoc."},{"key":"97730_CR56","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0960-8966(96)00006-5","volume":"6","author":"PA Roest","year":"1996","unstructured":"Roest, P. A. et al. Application of in vitro Myo-differentiation of non-muscle cells to enhance gene expression and facilitate analysis of muscle proteins. Neuromuscul Disord 6, 195\u2013202. https:\/\/doi.org\/10.1016\/0960-8966(96)00006-5 (1996).","journal-title":"Neuromuscul Disord"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97730-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97730-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97730-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T10:47:09Z","timestamp":1670064429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97730-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["97730"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-97730-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.02.24.962316","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"assertion":[{"value":"22 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18188"}}